ArticleChina CDC weekly2023
Changes in HIV-1 Subtypes/Sub-Subtypes, and Transmitted Drug Resistance Among ART-Naïve HIV-Infected Individuals - China, 2004-2022.
Article in China CDC weekly, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 53 citations in OpenAlex.
- From giant components to communities: community-level insights for prioritizing interventions within large clusters of HIV-1 transmission networks.Infectious Disease Modelling · 2027Article
- Transmitted and pretreatment drug resistance among 69 HIV-1 CRFs in China: the first systematic analysis.Emerging microbes & infections · 2026Article
- Molecular footprints of a traveling epidemic: CRF01_AE-cluster 5 (01_C5) might spread across Northeast and South China via middle-aged MSM.Emerging microbes & infections · 2026Article
- HIV-1 transmitted drug resistance in Shanghai, 2018-2024: population mobility shapes cross-population TDR transmission dynamics.Emerging microbes & infections · 2026Article
- Evolving HIV-1 epidemiology, drug resistance and socio-demographics among blood donors in Dalian, Northeastern China, 2011-2024.Vox sanguinis · 2026Article
- G-HIV: An Integrated Long-Read Sequencing and Automated Bioinformatics Platform for Rapid and Precise HIV-1 Surveillance.Microorganisms · 2026Article
- Changes in RPV Resistance-Related Mutations Among Antiretroviral Therapy-Naïve HIV-1-Positive Individuals - China, 2004-2023.China CDC weekly · 2026Article
- Virologic Outcomes of Common First-Line Antiretroviral Regimens Among Adults with HIV - China, 2021-2023.China CDC weekly · 2026Article
- Identification of a novel HIV-1 circulating recombinant form (CRF209_cpx) and its descendant unique recombinant form (URF) CRF209_cpx/B among MSM in Guangdong, southern China.Virology journal · 2026Article
- [Impact of HIV-1 genotypes and population mobility on HIV-1 transmission in Guangzhou: a molecular transmission network analysis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Article
- Article
- Development of a Subsequence Correlation Coefficient Feature Vector Method for High-Resolution HIV-1 Subtype Classification - China, 2004-2022.China CDC weekly · 2026Article
- Expert consensus on the clinical management of HIV late presentation.Infectious diseases & immunity · 2026Article
- Identification of a novel HIV-1 circulating recombinant form (CRF161_0107) from CRF01_AE-C5 lineage among men who have sex with men in southwestern China.Virologica Sinica · 2026Article
- HIV-1 genetic diversity and pretreatment drug resistance in Xishuangbanna, a China-Myanmar-Laos border region.BMC infectious diseases · 2026Article
- Geographical and temporal trends of HIV-1 subtypes and drug resistance in China: a nationwide study over two decades (2003-2024).The Journal of general virology · 2026Article
- Characterization of sexually acquired HIV-1 transmission networks and genetic variation in northern frontier China, 2021-2024.Frontiers in public health · 2026Article
- Molecular genetic characterization of a novel HIV-1 circulating recombinant form (CRF205_0107) among men who have sex with men in Hangzhou, China.Frontiers in microbiology · 2026Article
- Molecular transmission network and drug resistance analysis of 404 HIV-1 cases infected through commercial heterosexual contact (2020-2024).Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The efficacy of treatment and clinical outcomes may be jeopardized by factors such as transmitted drug resistance (TDR) and the genetic diversity of the human immunodeficiency virus type 1 (HIV-1). This comprehensive study aims to examine the alterations in HIV-1 subtypes or sub-subtypes and TDR among Chinese individuals, who have been diagnosed with HIV infection and are previously untreated with antiretroviral therapy (ART), across the span of 2004 to 2022. Methods: Sequences of the HIV-1 Results: Among the 57,902 ART-naïve individuals infected with HIV, there was a notable decline in the prevalence of CRF01_AE, B, and C from 37.3%, 24.1%, and 1.3% respectively in 2004-2007 to 29.4%, 7.3%, and 0.2% respectively in 2020-2022. Simultaneously, a significant increase was observed in the proportions of CRF07_BC, CRF08_BC, CRF55_01B, other CRFs, and URFs, from 24.1%, 11.5%, 0.1%, 0.4%, and 0.9% respectively in 2004-2007 to 40.8%, 11.5%, 3.8%, 3.7%, and 2.8% respectively in 2020-2022 (all Conclusions: The total prevalence of TDR in China has achieved a moderate level (7.8%) from 2020 to 2022, with NNRTI resistance standing prominently at 6.7%. Consequently, measures to curb TDR are urgently required, particularly among ART-naïve HIV-infected individuals in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.